Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271191 | 0.98 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5275354 | 0.97 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5273395 | 0.96 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5276150 | 0.96 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5273457 | 0.95 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5275532 | 0.94 | TP53 (0.46) | TP53MAPTGPBAR1CYSLTR1KMT2A | |
| SCHEMBL5272902 | 0.89 | TP53 (0.46) | TP53MAPTKMT2ANPC1RAB9A | |
| SCHEMBL5278464 | 0.88 | PKM (0.45) | TP53MAPTGPBAR1CYSLTR1NPC1 | |
| SCHEMBL5277813 | 0.85 | PLA2G4B (0.46) | TP53MAPTGPBAR1CYSLTR1NPC1 | |
| SCHEMBL5270863 | 0.85 | TP53 (0.46) | TP53MAPTCYSLTR1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301033-B2 | PPAR-activating compound | KOWA CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| EP-1857447-A1 | PPAR-ACTIVATING COMPOUND | Kowa Company, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20060167058-A1 | PPAR-activating compound | KOWA CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167058-A1 | PPAR-activating compound | PPARA, PPARG, PPARD | TP53 4064/4885MAPT 4734/4885GPBAR1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.